Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in an ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

In the US, the CDC recommends shingles vaccination for all adults aged 50 and older. However, uptake has been low, partly due to limited awareness, cost concerns, and missed opportunities during ...

The recombinant herpes zoster vaccine (Shingrix) was not only associated with a reduced risk of herpes zoster ophthalmicus ...

Despite how common shingles is, there's a lot of misinformation out there—which we're happy to clear up. Here are six myths and the facts you need to protect yourself.

Shingles will strike 1 in 3 Americans during their lifetimes — most between ages 60 and 70. Folks in their 60s get shingles at roughly twice the rate as folks in their 50s, reports the CDC.

The weight of the asphalt shingles stacked on the rooftop was too much, it caused the roof and the walls to collapse, he said. "I couldn't believe it," he said. It is a modest house.